Outcome data on the use of cangrelor in older patients is limited. This post-hoc analysis of the ARCANGELO study aims to assess bleeding and ischemic outcomes with the transition from cangrelor to any oral P2Y inhibitors in age-stratified subgroups (≥75 years - older, <75 years - younger) of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Out of 995 patients, 215 (21.
View Article and Find Full Text PDFAust N Z J Obstet Gynaecol
December 2024
Background: Delivery of safe maternity care requires not only individual competence but collective team work, influenced by knowledge, team culture and physical working spaces. The ideal layout for a birthing unit is not known, but deliberate changes to the built environment can influence patient care.
Aims: To explore the impact of creation of an open 'hub' on maternity team culture in a tertiary birthing unit and how physical changes to the environment shape values and practice.
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFBackground And Objectives: The risk profiles, procedural characteristics, and clinical outcomes for women undergoing bifurcation percutaneous coronary intervention (PCI) are not well defined compared to those in men.
Methods: COronary BIfurcation Stenting III (COBIS III) is a multicenter, real-world registry of 2,648 patients with bifurcation lesions treated with second-generation drug-eluting stents. We compared the angiographic and procedural characteristics and clinical outcomes based on sex.